KR101452792B1 - 펙소페나딘 현탁액 제형 - Google Patents

펙소페나딘 현탁액 제형 Download PDF

Info

Publication number
KR101452792B1
KR101452792B1 KR1020087014471A KR20087014471A KR101452792B1 KR 101452792 B1 KR101452792 B1 KR 101452792B1 KR 1020087014471 A KR1020087014471 A KR 1020087014471A KR 20087014471 A KR20087014471 A KR 20087014471A KR 101452792 B1 KR101452792 B1 KR 101452792B1
Authority
KR
South Korea
Prior art keywords
aqueous pharmaceutical
volume
weight
pharmaceutical suspension
sodium phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087014471A
Other languages
English (en)
Korean (ko)
Other versions
KR20080074180A (ko
Inventor
프라풀라 아그라왈라
카지미에르즈 크르잔
라지브 하리브학티
매튜 머메이
커티스 제이. 포첼로
개리 리 실베이
빈 트란
Original Assignee
사노피-아벤티스 유.에스. 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38120312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101452792(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 사노피-아벤티스 유.에스. 엘엘씨 filed Critical 사노피-아벤티스 유.에스. 엘엘씨
Publication of KR20080074180A publication Critical patent/KR20080074180A/ko
Application granted granted Critical
Publication of KR101452792B1 publication Critical patent/KR101452792B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
KR1020087014471A 2005-12-14 2006-12-12 펙소페나딘 현탁액 제형 Expired - Fee Related KR101452792B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75030305P 2005-12-14 2005-12-14
US60/750,303 2005-12-14
PCT/US2006/047393 WO2007070517A2 (en) 2005-12-14 2006-12-12 Fexofenadine suspension formulation

Publications (2)

Publication Number Publication Date
KR20080074180A KR20080074180A (ko) 2008-08-12
KR101452792B1 true KR101452792B1 (ko) 2014-10-22

Family

ID=38120312

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087014471A Expired - Fee Related KR101452792B1 (ko) 2005-12-14 2006-12-12 펙소페나딘 현탁액 제형

Country Status (38)

Country Link
US (1) US8933097B2 (enExample)
EP (1) EP1965768B1 (enExample)
JP (1) JP5308824B2 (enExample)
KR (1) KR101452792B1 (enExample)
CN (1) CN101316580B (enExample)
AR (1) AR058323A1 (enExample)
AT (1) ATE431137T1 (enExample)
AU (1) AU2006326551B2 (enExample)
BR (1) BRPI0619895B1 (enExample)
CA (1) CA2633086C (enExample)
CR (1) CR9993A (enExample)
CY (1) CY1109320T1 (enExample)
DE (1) DE602006006870D1 (enExample)
DK (1) DK1965768T3 (enExample)
DO (1) DOP2006000274A (enExample)
EC (1) ECSP088532A (enExample)
EG (1) EG25866A (enExample)
ES (1) ES2327168T3 (enExample)
HN (1) HN2008000875A (enExample)
HR (1) HRP20090411T1 (enExample)
IL (1) IL192067A (enExample)
JO (1) JO2549B1 (enExample)
MA (1) MA30152B1 (enExample)
MY (1) MY146988A (enExample)
NO (1) NO339877B1 (enExample)
NZ (1) NZ568943A (enExample)
PE (1) PE20071003A1 (enExample)
PL (1) PL1965768T3 (enExample)
PT (1) PT1965768E (enExample)
RS (1) RS51135B (enExample)
RU (1) RU2405538C2 (enExample)
SI (1) SI1965768T1 (enExample)
TN (1) TNSN08186A1 (enExample)
TW (1) TWI377061B (enExample)
UA (1) UA89584C2 (enExample)
UY (1) UY30021A1 (enExample)
WO (1) WO2007070517A2 (enExample)
ZA (1) ZA200803985B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101546774B1 (ko) 2008-07-29 2015-08-24 엘지전자 주식회사 휴대 단말기 및 그 동작제어 방법
BR112014009547A8 (pt) 2011-10-19 2018-01-23 Scherer Technologies Llc R P composição farmacêutica para administração oral, e, sistema de liberação para a administração oral de uma composição farmacêutica bifásica
EP3016635A1 (en) * 2013-07-01 2016-05-11 Aventisub LLC Liquid pharmaceutical composition for oral administration comprising fexofenadine
WO2015003109A1 (en) * 2013-07-03 2015-01-08 R.P. Scherer Technologies, Llc Capsule formulation comprising fexofenadine
CN103610645B (zh) * 2013-11-25 2016-05-11 浙江万晟药业有限公司 一种非索非那定盐酸盐的药物组合物及制备方法
CN106806346B (zh) * 2015-12-01 2020-09-11 国药集团广东环球制药有限公司 一种非索非那定盐酸盐干混悬剂制剂及其制备方法
CN109906079B (zh) * 2016-06-16 2022-09-30 库蒂斯制药公司 用于质子泵抑制剂混悬剂的组合物和方法
CN110730656B (zh) 2017-06-02 2022-09-16 特一华制药株式会社 水难溶性成分增溶胶束及含有该胶束的液体制剂
US10751333B1 (en) 2019-07-16 2020-08-25 Cutispharma, Inc. Compositions and kits for omeprazole suspension
US11633478B2 (en) 2019-07-16 2023-04-25 Azurity Pharmaceuticals, Inc. Compositions and kits for Omeprazole suspension
WO2022038474A1 (en) * 2020-08-18 2022-02-24 Innate S.R.L. Injectable composition and use of said composition
WO2022175829A1 (en) 2021-02-17 2022-08-25 Cellix Bio Private Limited Topical formulations and compositions
EP4456880A1 (en) * 2021-12-29 2024-11-06 Opella Healthcare Group SAS Compositions containing fexofenadine
CN115715759B (zh) * 2022-11-03 2024-01-12 京海盛达(北京)科技有限公司 一种抗组胺混悬剂及其制备方法
CR20240566A (es) 2023-01-20 2025-02-25 Opella Healthcare Group Sas Formulaciones de fexofenadina sin parabenos

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004066974A1 (en) 2003-01-30 2004-08-12 Ethypharm Taste-masking coated particles, process for the preparation thereof and orodispersible tablets containing said coated particles

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4829064A (en) 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
EP0766668B1 (en) * 1994-05-18 2002-07-17 Aventis Pharmaceuticals Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
US6319513B1 (en) * 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
GB9822170D0 (en) 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
PT1414453E (pt) 2001-07-31 2008-05-29 Texcontor Ets Polimorfo de cloridrato de fexofenadina
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
PL2486942T3 (pl) * 2004-11-24 2019-05-31 Meda Pharmaceuticals Inc Kompozycje zawierające azelastynę oraz sposoby ich stosowania
EP1910294A1 (en) 2005-07-27 2008-04-16 Sandoz AG A process for the preparation of substituted phenyl ether compounds and rosiglitazone
JP5133244B2 (ja) * 2005-08-05 2013-01-30 ルピン・リミテッド フェキソフェナジンの経口用医薬懸濁組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004066974A1 (en) 2003-01-30 2004-08-12 Ethypharm Taste-masking coated particles, process for the preparation thereof and orodispersible tablets containing said coated particles

Also Published As

Publication number Publication date
AU2006326551A1 (en) 2007-06-21
JP5308824B2 (ja) 2013-10-09
ZA200803985B (en) 2009-03-25
PL1965768T3 (pl) 2009-11-30
JO2549B1 (en) 2010-09-05
CY1109320T1 (el) 2014-07-02
EG25866A (en) 2012-09-12
TWI377061B (en) 2012-11-21
RS51135B (sr) 2010-10-31
IL192067A0 (en) 2009-02-11
MY146988A (en) 2012-10-15
DOP2006000274A (es) 2007-10-15
ECSP088532A (es) 2008-08-29
HK1123197A1 (en) 2009-06-12
MA30152B1 (fr) 2009-01-02
BRPI0619895A2 (pt) 2011-10-25
RU2405538C2 (ru) 2010-12-10
ATE431137T1 (de) 2009-05-15
RU2008128418A (ru) 2010-01-20
WO2007070517A3 (en) 2007-08-23
EP1965768B1 (en) 2009-05-13
EP1965768A2 (en) 2008-09-10
DE602006006870D1 (de) 2009-06-25
HN2008000875A (es) 2012-01-30
CA2633086A1 (en) 2007-06-21
BRPI0619895B1 (pt) 2022-04-12
NO20082904L (no) 2008-09-10
SI1965768T1 (sl) 2009-10-31
CN101316580B (zh) 2011-11-16
DK1965768T3 (da) 2009-09-07
NO339877B1 (no) 2017-02-13
HRP20090411T1 (hr) 2010-01-31
AR058323A1 (es) 2008-01-30
KR20080074180A (ko) 2008-08-12
JP2009519935A (ja) 2009-05-21
AU2006326551B2 (en) 2012-06-07
UA89584C2 (en) 2010-02-10
US20080299211A1 (en) 2008-12-04
PT1965768E (pt) 2009-08-07
CR9993A (es) 2008-09-23
ES2327168T3 (es) 2009-10-26
TW200812581A (en) 2008-03-16
NZ568943A (en) 2010-04-30
TNSN08186A1 (en) 2009-10-30
PE20071003A1 (es) 2007-10-03
UY30021A1 (es) 2007-07-31
US8933097B2 (en) 2015-01-13
IL192067A (en) 2010-12-30
WO2007070517A2 (en) 2007-06-21
CN101316580A (zh) 2008-12-03
CA2633086C (en) 2011-10-18

Similar Documents

Publication Publication Date Title
US8933097B2 (en) Fexofenadine suspension formulation
US6150366A (en) Ziprasidone formulations
UA89513C2 (uk) Стабільна композиція з наночастинок ралоксифену гідрохлориду
CN112220748B (zh) 地氯雷他定口服液制剂及其制备方法
SK1722002A3 (en) Beta-carboline drug products
HK1123197B (en) Fexofenadine suspension formulation
US11179338B1 (en) Powder for oral suspension containing tadalafil
US20040142903A1 (en) Bioavailable fenofibrate compositions, methods for treating hyperlipidemia and hypercholesterolemia and processes for the preparation of such compositions
CN121081383A (zh) 布瑞哌唑混悬液及其用途
EP4543416A1 (en) Oral dosage forms of elraglusib
HK1024184B (en) Ziprasidone formulations

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20171012

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20180918

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20191015

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20191015